| Patient | Jacqueline Mary du Pré |
|---|---|
| Date of birth | 1945-01-26 |
| Identifiers | MRN HR-ML039-SYN-TD; SSN (made up) 000-39-7062 |
| Document date | 1973-10-12 |
| Author | Imogen Thackeray-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six months: first 600 mg dose of ocrelizumab. [S]
Ms. du Pré comes on the day of her first 600 mg dose of ocrelizumab, six months after starting treatment. She has had no relapse and no new symptoms. She played chamber music in public in August and last month, has a concerto booked for the spring, and gives master classes at a conservatory twice a month. Faint tingling in the left fingertips comes only after long practice. Fatigue is manageable with swimming and an after-lunch rest. She had influenza and COVID-19 vaccines a month ago. She asked when it would be safe to try for a baby, perhaps in a year or two. [S]
| Element | Detail |
|---|---|
| Disease activity | No relapse in six months; re-baseline MRI clear |
| Treatment | Ocrelizumab 600 mg today |
| Music | Performing chamber music; concerto booked; teaching master classes |
| Her question | Pregnancy in a year or two |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy manageable; no fever |
| Neurological | Positive | Faint tingling in the left fingertips after long practice only |
| Genitourinary | Negative | No urinary symptoms |
| Respiratory | Negative | No cough |
| Musculoskeletal | Negative | Neck stiffness after practice, better with stretching |
| Psychiatric | Negative | Happy to be playing; PHQ-9 3, GAD-7 3; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule twice daily for 5 days | Oral route | 1973-06-15 to 1973-06-19 | completed | S |
| Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days | 1 g daily for 3 days | Intravenous route | 1973-03-24 to 1973-03-26 | completed | S |
| Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily | One capsule daily | Oral route | 1973-03-23 | active | S |
| Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion | 300 mg on days 1 and 15, then 600 mg every 6 months | Intravenous route | 1973-04-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1973-10-12 | Body height | 173 | cm | S |
| 1973-10-12 | Body weight | 63.8 | kg | S |
| 1973-10-12 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 1973-10-12 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1973-10-12 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1973-10-12 | Heart rate | 68 | /min | S |
| 1973-10-12 | Respiratory rate | 14 | /min | S |
| 1973-10-12 | Body temperature | 36.5 | Cel | S |
| 1973-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1973-10-12 | Hemoglobin [Mass/volume] in Blood | 13.7 | g/dL | 12-15.5 g/dL | Normal | S |
| 1973-10-12 | Leukocytes [#/volume] in Blood by Automated count | 6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1973-10-12 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1973-10-12 | Platelets [#/volume] in Blood by Automated count | 238 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1973-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1973-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M | 121 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1973-10-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 1973-10-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 8-35 U/L | Normal | S |
| 1973-10-12 | IgG [Mass/volume] in Serum or Plasma | 930 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1973-10-12 | IgM [Mass/volume] in Serum or Plasma | 46 | mg/dL | 40-230 mg/dL | Normal | S |
| 1973-10-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Normal | S |
| 1973-10-12 | Hepatitis B virus surface Ab [Units/volume] in Serum | 6 | m[IU]/mL | 10 mIU/mL or more is protective | Low | S |
| 1973-10-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1973-10-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S | ||
| 1973-10-12 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 18.5 | s | S | ||
| 1973-10-12 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 19.5 | s | S |
Vital signs recorded on 1973-10-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 63.8 kg; blood pressure 112/70 |
| Neurological | Vibration slightly reduced in the left fingertips only; otherwise normal. Nine-hole peg test 18.5 seconds right, 19.5 seconds left. EDSS 1.0 |
| Skin | No rash |
| Psychiatric | Bright and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week | resolved | confirmed | R20.2 | S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit. |
| Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosis | active | confirmed | G35.A | S — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973. |
| Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis | active | confirmed | E55.9 | S — Synthetic finding. |
| Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent infection; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with lymphocytes | Before each ocrelizumab dose | Completed today | Hemoglobin 13.7 g/dL, white cells 6.0, lymphocytes 1.4, platelets 238 |
| Laboratory | Immunoglobulins (IgG, IgM) | At baseline and before each ocrelizumab dose | Completed today | IgG 930 mg/dL, IgM 46 mg/dL (low-normal) |
| Laboratory | Kidney and liver tests | Before each dose | Completed today | Creatinine 0.70 mg/dL, eGFR 121; ALT 18 U/L, AST 20 U/L |
| Laboratory | 25-hydroxyvitamin D | Every six to twelve months on replacement | Completed today | 38 ng/mL |
| Laboratory | Hepatitis B surface antibody after vaccination | One to two months after the last dose | Completed today | 6 mIU/mL, not protective; drawn late (deviation recorded at the fourth visit) |
| Laboratory | Pregnancy test | Before each ocrelizumab dose | Completed today | Urine pregnancy test negative |
| Imaging | MRI of the brain | Yearly on treatment | Due | Next about a year after the re-baseline scan |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 18.5 seconds right, 19.5 seconds left |
| Examination | Neurological examination and EDSS | Each review | Completed today | EDSS 1.0; no change |
| Medication safety | Infections on anti-CD20 therapy | Each review | Completed today | None since June |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 3 (item 9 scored 0), GAD-7 3 |
| Self-management | Pregnancy planning | At each review in women who may become pregnant | Completed today | Plan to conceive a few months after a dose, with a preconception visit |
| Self-management | Fatigue: causes and management | Each review | Completed today | Managed with exercise and pacing |
Goal progress:
Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)
Follow-up: Ocrelizumab every six months; MRI of the brain in about nine months; primary care review in six months; preconception visit when she is ready. [S]